Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Income towards Parent Company (2020 - 2026)

Rani Therapeutics Holdings' Income towards Parent Company history spans 7 years, with the latest figure at -$8.0 million for Q1 2026.

  • On a quarterly basis, Income towards Parent Company rose 37.08% to -$8.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$35.7 million, a 34.64% increase, with the full-year FY2025 number at -$40.4 million, up 28.65% from a year prior.
  • Income towards Parent Company came in at -$8.0 million for Q1 2026, up from -$8.5 million in the prior quarter.
  • The five-year high for Income towards Parent Company was -$7.9 million in Q3 2025, with the low at -$18.7 million in Q2 2023.
  • Historically, Income towards Parent Company has averaged -$13.9 million across 5 years, with a median of -$14.1 million in 2023.
  • Biggest five-year swings in Income towards Parent Company: plummeted 191.08% in 2022 and later surged 45.95% in 2025.
  • Year by year, Income towards Parent Company stood at -$17.4 million in 2022, then increased by 19.09% to -$14.1 million in 2023, then dropped by 11.86% to -$15.7 million in 2024, then skyrocketed by 45.95% to -$8.5 million in 2025, then rose by 5.68% to -$8.0 million in 2026.
  • Business Quant data shows Income towards Parent Company for RANI at -$8.0 million in Q1 2026, -$8.5 million in Q4 2025, and -$7.9 million in Q3 2025.